Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher
LONDON - abrdn Asian Income Fund Limited has declared its first quarterly interim dividend for the year ending December 31, 2025, at 3.65 pence per share, with a payment date set for May 23, 2025. Shareholders on record by April 25, 2025, will be eligible for the dividend, which precedes the ex-dividend date of April 24, 2025.
The dividend announcement follows the Company’s adoption of an enhanced dividend policy earlier this year, aimed at attracting a broader investor base and responding to the sustained demand for yield in the current interest rate climate. The annualized dividend yield based on the share price of 210p as of March 31, 2025, is 6.95%.
Despite the recent market fluctuations, particularly due to the U.S. Government’s tariff announcements, the Board expresses confidence in the Company’s investment strategy. The focus on high-quality, dividend-paying companies is believed to provide a solid foundation for positive long-term outcomes.
The Asia-Pacific markets are deemed to offer diverse income sources, with strong corporate balance sheets and a commitment to shareholder returns. The Company’s portfolio includes a range of sectors, from technology firms in Taiwan and South Korea to financial institutions in Singapore and India, aiming to provide a balanced income strategy and exposure to long-term growth trends.
Shareholders also have the option to reinvest their dividends through a Dividend Reinvestment Plan (DRIP), managed by Computershare Investor Services PLC, with the election deadline being May 1, 2025.
The dividend policy of the Company, as announced on January 16, 2025, sets the dividend at 1.5625% per quarter of the Company’s net asset value (NAV), totaling approximately 6.25% of NAV annually. The current interim dividend is calculated based on the NAV of 233.63p per share as of March 31, 2025.
This information is based on a press release statement issued by abrdn Asian Income Fund Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.